What is RDGL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RDGL?

P/E (TTM) is n/a and 52-week range is $0.04 to $0.12 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RDGL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RDGL?

The company profile lists revenue (TTM) near $99K, net income (TTM) near $-359M, EPS (TTM) near $-0.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vivos Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Richland, Washington, US, 493.9M shares outstanding, ISIN US92858K2042 when available from company profile and filing metadata.

Vivos Inc

$RDGL

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.05

+4.79%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.

Website

www.radiogel.com/

IPO

2001-08-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)